Adalimumab vs Vedolizumab for Treatment of Ulcerative Colitis and Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Inflammatory Bowel Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD
Inflamm. Bowel Dis. 2021 Nov 09;[EPub Ahead of Print], A Moens, B Verstockt, D Alsoud, J Sabino, M Ferrante, S VermeireFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.